AGTX · Agentix Corp.
Market Cap
$801,339
Shares
40.07M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.02
Open$0.02
Day$0.02–0.02
52W close$0.02–0.05
Avg vol 30d35K
Short int13 · 0.0% float · 1.0d
Short vol100%
DataMar 2020–Aug 2026
Filing10-Q · Aug 10
Raw chart and full-history price indicators begin at the captured split on Feb 25, 2020; bars on opposite sides are not compared.
Up next
FQ2-27 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−69%
below
Price vs 50-day avg
−47%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
9%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−54%
trailing
6-month return
−44%
trailing
YTD return
−47%
this year
Relative strength
−55%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
13
low risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
0%
Y/Y
Free cash flow
$-109.9K
Quant / Vol
risk profile
Volatility
470%
annualized · 1-yr
Max drawdown
−95%
past year
ATR
26.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−69%
Bearish
Price vs 50-day avg
−47%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
9%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 9%
Range high $0
vs 200-day avg -69%
vs 50-day avg -47%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AGTX
this stock
Agentix Corp.
|
$801,339 | -46.7% | -100.0% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Performance
Raw-price comparisons begin at the captured split on Feb 25, 2020; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AGTX | -5.2% | -54.4% | -43.7% | +0.0% | -46.7% |
| SPY | -0.2% | +3.4% | +11.8% | +2.5% | +12.3% |
| vs SPY | -5.0% | -57.8% | -55.5% | -2.5% | -59.0% |